Tumor necrosis factor receptor-associated factor 6 (TRAF6), the crucial adaptor molecule of receptor activator of NF-κB (RANK), plays an essential role in governing the formation of multi-nucleated osteoclasts. TRAF6 is a RING-dependent ubiquitin (Ub) ligase that in conjunction with Ubc13/ Uev1A catalyzes its own auto-ubiquitination via Lys63-linked poly-Ub chains. While the receptoradaptor function of TRAF6 in RANK signaling is well understood, the significance of its Ub ligase activity in this process remains largely unknown. In this study, we show that retroviral expression of TRAF6, but not a RING mutant of TRAF6 was able to rescue TRAF6-deficient monocytes for the activation of IKK and osteoclast differentiation by RANKL. Furthermore, a catalytically inactive Ubc13 or stable knockdown of Ubc13 significantly prevents RANK-mediated TRAF6 ubiquitination and NF-κB and JNK activation. These data establish a signaling cascade in which regulated Lys63-linked TRAF6 auto-ubiquitination is the critical upstream mediator of osteoclast differentiation.
TRAF6, a crucial adaptor molecule in innate and adaptive immunity, contains three distinct functional domains. The C-terminal TRAF domain facilitates oligomerization and sequence-specific interaction with receptors or other adaptor proteins. In conjunction with the dimeric E2 enzyme Ubc13-Uev1A, the N-terminal RING domain of TRAF6 functions as an E3 ubiquitin (Ub) ligase that facilitates its own site-specific ubiquitination through the generation of a Lys-63-linked poly-Ub chain. This modification does not cause its proteasomal degradation but rather serves as a scaffold to activate both the IKK and stress kinase pathways. Connecting the N-and C-terminal regions, the four internal zinc finger (ZF) motifs have yet to be functionally defined. In this study, we examined the role of the ZF domains in interleukin-1, lipopolysaccharide, and RANKL signaling by reconstitution of TRAF6-deficient cells with point mutations or deletions of these ZF motifs. Although ZF domains 2-4 are dispensable for activating IKK, p38, and JNK by interleukin-1 and lipopolysaccharide, the first ZF domain together with an intact RING domain of TRAF6 is essential for activating these pathways. Furthermore, TRAF6 autoubiquitination and its interaction with Ubc13 are dependent on ZF1 and an intact RING domain. Additionally, expression of TRAF6 lacking ZF2-4 in TRAF6-deficient monocytes rescues RANKL-mediated osteoclast differentiation and LPS-stimulated interleukin-6 production. These data provide evidence for the critical role of the Ub ligase activity of TRAF6, which is coordinated via the RING domain and ZF1 to supply the necessary elements in signaling by cytokines dependent upon TRAF6.TRAF6, a member of the tumor necrosis factor receptorassociated factor (TRAF) 2 family, is a crucial docking molecule that mediates signaling events initiated by cytokines of the tumor necrosis factor superfamily, interleukin-1 (IL-1) family, and pathogen-associated microbial patterns that are recognized by the Toll-like receptor family (1, 2). Following binding to their respective receptors, these ligands induce a cascade of signaling events leading to the activation of transcription factors, such as the nuclear factor-B (NF-B) and AP1 (activator protein-1) family, through activation of upstream kinases, including inhibitor of -B kinase (IKK) and the mitogen-activated protein kinase (MAPK) family (i.e. p38, JNK, and extracellular signal-regulated kinase) (1, 2). As a result, these ligands induce numerous genes involved in the innate immune and inflammatory responses. Generation of TRAF6-deficient mice revealed that in addition to playing a critical role in the innate and adaptive immunity, TRAF6 has a crucial role in a wide range of biological functions, such as lymph node organogenesis, formation of skin appendices, nervous system development, and bone metabolism (3-9). TRAF6 contains three major domains: 1) the C-terminal domain, which facilitates oligomerization and interaction with receptors and other adaptor proteins in a sequence-specific manner; 2) t...
While G protein‐coupled receptors (GPCRs) are known to be excellent drug targets, the second largest family of adhesion‐GPCRs is less explored for their role in health and disease. ADGRF1 (GPR110) is an adhesion‐GPCR and has an important function in neurodevelopment and cancer. Despite serving as a poor predictor of survival, ADGRF1’s coupling to G proteins and downstream pathways remain unknown in cancer. We evaluated the effects of ADGRF1 overexpression on tumorigenesis and signaling pathways using two human epidermal growth factor receptor‐2‐positive (HER2+) breast cancer (BC) cell‐line models. We also interrogated publicly available clinical datasets to determine the expression of ADGRF1 in various BC subtypes and its impact on BC‐specific survival (BCSS) and overall survival (OS) in patients. ADGRF1 overexpression in HER2+ BC cells increased secondary mammosphere formation, soft agar colony formation, and % of Aldefluor‐positive tumorigenic population in vitro and promoted tumor growth in vivo. ADGRF1 co‐immunoprecipitated with both Gαs and Gαq proteins and increased cAMP and IP1 when overexpressed. However, inhibition of only the Gαs pathway by SQ22536 reversed the pro‐tumorigenic effects of ADGRF1 overexpression. RNA‐sequencing and RPPA analysis revealed inhibition of cell cycle pathways with ADGRF1 overexpression, suggesting cellular quiescence, as also evidenced by cell cycle arrest at the G0/1 phase and resistance to chemotherapy in HER2+ BC. ADGRF1 was significantly overexpressed in the HER2‐enriched BC compared to luminal A and B subtypes and predicted worse BCSS and OS in these patients. Therefore, ADGRF1 represents a novel drug target in HER2+ BC, warranting discovery of novel ADGRF1 antagonists.
Purpose Adhesion G protein coupled receptors (aGPCRs) remains least explored GPCRs family for their role in health and disease. The aGPCR, ADGRF1 (GPR110), is overexpressed and predicts poor survival in various cancer types. However, ADGRF1's coupling to G proteins and downstream pathways remain unknown in cancer. We have reported that ADGRF1 is overexpressed in tumorigenic population and in anti‐HER2 therapy‐resistant derivatives of various HER2+ breast cancer (BC) cell line models. Further, we have reported that ADGRF1 knockdown reduces tumorigenesis and metastasis in HER2+ BC cells. In this study, we evaluated the effects of ADGRF1 overexpression (OE) on tumorigenesis, signaling pathways, and outcomes in HER2+ BC. Methods Stable clones of 2 HER2+ BC cell lines, BT474 and SKBR3, were generated to overexpress ADGRF1 construct in doxycycline‐inducible manner. The effect of ADGRF1 on tumorigenesis was evaluated in vitro using soft agar assays, mammosphere assay, and Aldefluor assay. The effect on the HER pathway was evaluated by assessing expression of phospho‐ and total‐HER1 and ‐HER2 and potency of anti‐HER2 drugs. G protein coupling of ADGRF1 was determined by co‐immunoprecipitation of Gαs and Gαq and detecting second messengers, cAMP and IP1, in presence/absence of synaptamide, an ADGRF1 agonist. Downstream pathways of ADGRF1 were explored by RNAseq and Reverse Phase Protein Arrays (RPPA) and functional assays. ADGRF1 expression was assessed in BC patients from The Cancer Genome Atlas. ADGRF1 OE effects on survival was evaluated using the Molecular Taxonomy of Breast Cancer International Consortium dataset. Results ADGRF1 OE enhanced the number of colonies and mammospheres and increased Aldefluor+ tumorigenic cell population, suggesting a role in tumorigenesis. ADGRF1 OE did not alter the expression total‐ or phospho‐HER1/‐HER2 proteins or efficacy of anti‐HER2 drugs. Overexpressed ADGRF1 co‐immunoprecipitated with Gαs and Gαq proteins and increased cAMP and IP1. However, inhibition of only the Gαs pathway by SQ22536 reversed the pro‐tumorigenic effects of ADGRF1 OE, suggesting pro‐tumorigenic effects of the ADGRF1‐Gαs pathway. Synaptamide, did not alter cAMP or IP1 with/without ADGRF1 OE or the number of mammospheres. Integration of RNA‐Seq and RPPA data showed that ADGRF1 OE inhibited cell cycle. We detected G0/1 arrest by cell cycle analysis with ADGRF1 OE. The protein level of the proliferation marker Ki67 was reduced upon ADGRF1 OE. Also, ADGRF1 OE led to a 10‐fold reduction in potency of docetaxel, a chemotherapy drug used in HER2+ BC. ADGRF1 was overexpressed and amplified in basal and HER2 compared to luminal A and B BCs. High ADGRF1 expression predicted poor survival in HER2 subtype, but not in basal BC. Conclusions: ADGRF1 represents a novel drug target in HER2+ BC, warranting discovery of novel ADGRF1 antagonists.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.